Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector

K. Oka, Ligia Belalcazar, C. Dieker, E. A. Nour, P. Nuno-Gonzalez, A. Paul, S. Cormier, J. K. Shin, M. Finegold, L. Chan

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We examined the efficacy and host response to the adenovirus (Ad)-mediated delivery of human apolipoprotein A-I (APOA1) gene to the liver of APOA1-/- mice. Administration of a first-generation vector (FGAd-AI) resulted in a transient appearance of APOA1 in plasma and induced an anti-APOA1 antibody titer, whereas treatment with a helper-dependent vector (HDAd-AI) resulted in sustained APOA1 expression without inducing an antibody titer. With these results, we studied the effects of FGAd vectors on APOAI expression by HDAd-AI vector. Co-treatment with an FGAd vector inhibited HDAd-AI- mediated APOA1 expression independent of transgene cassettes, but only FGAd-AI induced a humoral response. Furthermore, APOA1 mRNA levels in mice co-treated with FGAd vectors were much lower than those expected from the vector copy number, suggesting that DNA of FGAd vectors interferes with the HDAd-AI vector's APOA1 promoter. A single treatment with an HDAd-AI vector produced a supraphysiological plasma APOA1 level that gradually declined to about half the normal human level over the course of 2 years, associated with a plasma cholesterol level that is persistently higher than that in controls. This investigation provides the proof of principle that liver-directed HDAd gene delivery is effective for the long-term phenotypic correction of monogenic hypoalphalipoproteinemia.

Original languageEnglish (US)
Pages (from-to)191-202
Number of pages12
JournalGene Therapy
Volume14
Issue number3
DOIs
StatePublished - Feb 2007
Externally publishedYes

Fingerprint

Hypoalphalipoproteinemias
Adenoviridae
Liver
Transgenes
Genes
Anti-Idiotypic Antibodies
Cholesterol
Messenger RNA
Antibodies
DNA

ASJC Scopus subject areas

  • Genetics

Cite this

Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector. / Oka, K.; Belalcazar, Ligia; Dieker, C.; Nour, E. A.; Nuno-Gonzalez, P.; Paul, A.; Cormier, S.; Shin, J. K.; Finegold, M.; Chan, L.

In: Gene Therapy, Vol. 14, No. 3, 02.2007, p. 191-202.

Research output: Contribution to journalArticle

Oka, K, Belalcazar, L, Dieker, C, Nour, EA, Nuno-Gonzalez, P, Paul, A, Cormier, S, Shin, JK, Finegold, M & Chan, L 2007, 'Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector', Gene Therapy, vol. 14, no. 3, pp. 191-202. https://doi.org/10.1038/sj.gt.3302819
Oka, K. ; Belalcazar, Ligia ; Dieker, C. ; Nour, E. A. ; Nuno-Gonzalez, P. ; Paul, A. ; Cormier, S. ; Shin, J. K. ; Finegold, M. ; Chan, L. / Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector. In: Gene Therapy. 2007 ; Vol. 14, No. 3. pp. 191-202.
@article{5e7a1a990c6e43e0aec7b46bcc19a27b,
title = "Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector",
abstract = "We examined the efficacy and host response to the adenovirus (Ad)-mediated delivery of human apolipoprotein A-I (APOA1) gene to the liver of APOA1-/- mice. Administration of a first-generation vector (FGAd-AI) resulted in a transient appearance of APOA1 in plasma and induced an anti-APOA1 antibody titer, whereas treatment with a helper-dependent vector (HDAd-AI) resulted in sustained APOA1 expression without inducing an antibody titer. With these results, we studied the effects of FGAd vectors on APOAI expression by HDAd-AI vector. Co-treatment with an FGAd vector inhibited HDAd-AI- mediated APOA1 expression independent of transgene cassettes, but only FGAd-AI induced a humoral response. Furthermore, APOA1 mRNA levels in mice co-treated with FGAd vectors were much lower than those expected from the vector copy number, suggesting that DNA of FGAd vectors interferes with the HDAd-AI vector's APOA1 promoter. A single treatment with an HDAd-AI vector produced a supraphysiological plasma APOA1 level that gradually declined to about half the normal human level over the course of 2 years, associated with a plasma cholesterol level that is persistently higher than that in controls. This investigation provides the proof of principle that liver-directed HDAd gene delivery is effective for the long-term phenotypic correction of monogenic hypoalphalipoproteinemia.",
author = "K. Oka and Ligia Belalcazar and C. Dieker and Nour, {E. A.} and P. Nuno-Gonzalez and A. Paul and S. Cormier and Shin, {J. K.} and M. Finegold and L. Chan",
year = "2007",
month = "2",
doi = "10.1038/sj.gt.3302819",
language = "English (US)",
volume = "14",
pages = "191--202",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector

AU - Oka, K.

AU - Belalcazar, Ligia

AU - Dieker, C.

AU - Nour, E. A.

AU - Nuno-Gonzalez, P.

AU - Paul, A.

AU - Cormier, S.

AU - Shin, J. K.

AU - Finegold, M.

AU - Chan, L.

PY - 2007/2

Y1 - 2007/2

N2 - We examined the efficacy and host response to the adenovirus (Ad)-mediated delivery of human apolipoprotein A-I (APOA1) gene to the liver of APOA1-/- mice. Administration of a first-generation vector (FGAd-AI) resulted in a transient appearance of APOA1 in plasma and induced an anti-APOA1 antibody titer, whereas treatment with a helper-dependent vector (HDAd-AI) resulted in sustained APOA1 expression without inducing an antibody titer. With these results, we studied the effects of FGAd vectors on APOAI expression by HDAd-AI vector. Co-treatment with an FGAd vector inhibited HDAd-AI- mediated APOA1 expression independent of transgene cassettes, but only FGAd-AI induced a humoral response. Furthermore, APOA1 mRNA levels in mice co-treated with FGAd vectors were much lower than those expected from the vector copy number, suggesting that DNA of FGAd vectors interferes with the HDAd-AI vector's APOA1 promoter. A single treatment with an HDAd-AI vector produced a supraphysiological plasma APOA1 level that gradually declined to about half the normal human level over the course of 2 years, associated with a plasma cholesterol level that is persistently higher than that in controls. This investigation provides the proof of principle that liver-directed HDAd gene delivery is effective for the long-term phenotypic correction of monogenic hypoalphalipoproteinemia.

AB - We examined the efficacy and host response to the adenovirus (Ad)-mediated delivery of human apolipoprotein A-I (APOA1) gene to the liver of APOA1-/- mice. Administration of a first-generation vector (FGAd-AI) resulted in a transient appearance of APOA1 in plasma and induced an anti-APOA1 antibody titer, whereas treatment with a helper-dependent vector (HDAd-AI) resulted in sustained APOA1 expression without inducing an antibody titer. With these results, we studied the effects of FGAd vectors on APOAI expression by HDAd-AI vector. Co-treatment with an FGAd vector inhibited HDAd-AI- mediated APOA1 expression independent of transgene cassettes, but only FGAd-AI induced a humoral response. Furthermore, APOA1 mRNA levels in mice co-treated with FGAd vectors were much lower than those expected from the vector copy number, suggesting that DNA of FGAd vectors interferes with the HDAd-AI vector's APOA1 promoter. A single treatment with an HDAd-AI vector produced a supraphysiological plasma APOA1 level that gradually declined to about half the normal human level over the course of 2 years, associated with a plasma cholesterol level that is persistently higher than that in controls. This investigation provides the proof of principle that liver-directed HDAd gene delivery is effective for the long-term phenotypic correction of monogenic hypoalphalipoproteinemia.

UR - http://www.scopus.com/inward/record.url?scp=33846554963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846554963&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302819

DO - 10.1038/sj.gt.3302819

M3 - Article

VL - 14

SP - 191

EP - 202

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 3

ER -